- Price
- $193.23
- Day
- +0.40%
- Mkt Cap
- $7.46B
- 52W Range
- $151.11 – $208.92
- Volume
- 299.6K
- Beta
- 0.94
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PITTSBURGH, Aug. 3, 2026 /PRNewswire/ -- The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today declared a third quarter dividend of $0.54 per share on common stock, payable September 10, 2026, to shareholders of record on August 14, 2026. The Board also declared a dividend of $0.5625 per share on preferred stock, payable September 1, 2026, to shareholders of record on August 14, 2026.
Read full article
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
Read full article
MSA Safety Incorporated (MSA) Q2 2026 Earnings Call Transcript
Read full article
AZIO AI Executes Master Services Agreement with AT&T to provide Fiber Interconnectivity on its first 500MW AI Data Campus PR News
Read full article
MSA Safety Incorporporated NYSE: MSA reported higher second-quarter sales, earnings and cash flow, while maintaining its outlook for mid-single-digit organic growth in 2026. The company also said it completed its acquisition of Autronica Fire and Security in early July.
Read full article
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment. The company said quantitative analysis of PET imaging demonstrated reductions in inflammatory activity in brain regions commonly affected by MSA, including the basal ganglia and cerebellar white matter.
Read full article
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA Pivotal Phase 3 trial activities on track to initiate by year-end 2026 Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value Peer-reviewed publication in NeuroImage validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA Strengthened the Board of Directors with the appointment of Ms Ann Cunningham A$3.98 million Australian R&D Tax Incentive refund received subsequent to quarter end, supporting continued development of Alterity's clinical programs Cash balance of A$37.3 million as at 30 June 2026 MELBOURNE, Australia and SAN FRANCISCO, July 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2026 (Q4 FY26). “This was a defining quarter for Alterity, highlighted by our positive End of Phase 2 meeting with the FDA that established a clear, efficient registrational pathway for ATH434,” said David Stamler, M.D.
Read full article
Second Quarter 2026 Highlights Achieved quarterly net sales of $503 million, a 6% GAAP increase and a 3% organic increase year-over-year Generated GAAP operating income of $112 million, or 22.2% of sales, and adjusted operating income of $121 million, or 24.1% of sales Recorded GAAP net income of $86 million, or $2.23 per diluted share, an increase of 40% year-over-year, and adjusted earnings of $93 million, or $2.40 per diluted share, an increase of 24% year-over-year Generated free cash flow of $83 million and returned $47 million of capital to shareholders via share repurchases and dividend payments Announced the acquisition of Autronica Fire and Security for ~$555 million, which closed in July, and raised annual dividend for 56th consecutive year PITTSBURGH, July 30, 2026 /PRNewswire/ -- Global provider of advanced industrial safety products and solutions that protect people and facility infrastructures, MSA Safety Incorporated (NYSE: MSA) today reported financial results for the second quarter of 2026. "I want to thank the MSA team for their disciplined execution across our business in the second quarter," said Steve Blanco, President and Chief Executive Officer of MSA Safety.
Read full article
MSA Safety (MSA) came out with quarterly earnings of $2.4 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.93 per share a year ago.
Read full article
While the top- and bottom-line numbers for MSA Safety (MSA) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
PITTSBURGH, July 21, 2026 /PRNewswire/ -- The Board of Directors of MSA Safety Inc. (NYSE: MSA), a global leader in the development of advanced industrial safety technology products and solutions, today announced that Octavio Marquez, president and chief executive officer of Diebold Nixdorf, has been elected to the company's Board of Directors. His election was part of the MSA Board's regular succession plans.
Read full article
Bessemer Group Inc. raised its stake in MSA Safety Incorporporated (NYSE: MSA) by 56.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 161,000 shares of the industrial products company's stock after purchasing an additional 58,220 shares during the
Read full article